EMA Authorised: Alimta (pemetrexed) — Eli Lilly Nederland B.V.

View source ↗

Summary

European Medicines Agency authorises Alimta (pemetrexed) for mesothelioma and non-small-cell lung carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Non-small-cell Lung
• Mesothelioma

Drugs mentioned

• Alimta (pemetrexed)

Snippet

Status: Authorised. Therapeutic area: Mesothelioma;Carcinoma, Non-Small-Cell Lung. MAH: Eli Lilly Nederland B.V.. Decision date: 16/01/2026